These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3074131)

  • 41. [Mechanism of acquired antiestrogen resistance and its management in breast cancer].
    Iino Y; Maemura M; Morishita Y
    Nihon Rinsho; 1997 May; 55(5):1149-54. PubMed ID: 9155167
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
    Johnston SR; Lu B; Dowsett M; Liang X; Kaufmann M; Scott GK; Osborne CK; Benz CC
    Cancer Res; 1997 Sep; 57(17):3723-7. PubMed ID: 9288779
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Recent progress of endocrine therapy in breast cancer].
    Nomura Y
    Gan To Kagaku Ryoho; 1992 Jun; 19(6):783-9. PubMed ID: 1605654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tamoxifen therapy in primary breast cancer: biology, efficacy, and side effects.
    Love RR
    J Clin Oncol; 1989 Jun; 7(6):803-15. PubMed ID: 2654333
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insights into how phosphorylation of estrogen receptor at serine 305 modulates tamoxifen activity in breast cancer.
    Kastrati I; Semina S; Gordon B; Smart E
    Mol Cell Endocrinol; 2019 Mar; 483():97-101. PubMed ID: 30659843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tamoxifen therapy in advanced breast cancer with positive estrogen receptors in postmenopausal women.
    Bono A; Fariselli G; Bettoni I; Alloisio M; Nicoli N; Di Pietro S
    Tumori; 1982 Apr; 68(2):143-7. PubMed ID: 7123673
    [No Abstract]   [Full Text] [Related]  

  • 47. Progress in the prevention of breast cancer: concept to reality.
    Jordan VC
    J Steroid Biochem Mol Biol; 2000 Nov; 74(5):269-77. PubMed ID: 11162935
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.
    Lykkesfeldt AE
    Acta Oncol; 1996; 35 Suppl 5():9-14. PubMed ID: 9142958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New antiestrogen shows promise in ER-positive breast cancers.
    Oncology (Williston Park); 1994 Aug; 8(8):58. PubMed ID: 7947003
    [No Abstract]   [Full Text] [Related]  

  • 50. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
    Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
    Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiestrogen-induced remissions in stage IV breast cancer.
    Manni A; Trujillo J; Marshall JS; Pearson OH
    Cancer Treat Rep; 1976 Oct; 60(10):1445-50. PubMed ID: 1021225
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of tamoxifen in the treatment and prevention of breast cancer.
    Jordan VC
    Curr Probl Cancer; 1992; 16(3):129-76. PubMed ID: 1582240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
    van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
    J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endoxifen, an Estrogen Receptor Targeted Therapy: From Bench to Bedside.
    Jayaraman S; Reid JM; Hawse JR; Goetz MP
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34480554
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term survival in primary breast cancer: correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy.
    Chrapusta SJ; Giermek J; Pieńkowski T
    Med Sci Monit; 2004 Oct; 10(10):CR577-86. PubMed ID: 15448598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemistry of tamoxifen therapy in breast cancer.
    Nicholson RI
    Biochem Soc Trans; 1979 Jun; 7(3):569-72. PubMed ID: 446863
    [No Abstract]   [Full Text] [Related]  

  • 57. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy.
    Osborne CK; Coronado EB; Robinson JP
    Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1189-96. PubMed ID: 3653212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
    Lykkesfeldt AE; Madsen MW; Briand P
    Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of tamoxifen as adjuvant therapy in stage II breast cancer: a long-term follow-up.
    Marshall JS; Gordon NH; Hubay CA; Pearson OH
    J Lab Clin Med; 1987 Mar; 109(3):300-7. PubMed ID: 3819572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A pure antiestrogen, ICI 182,780, stimulates the growth of tamoxifen-resistant KPL-1 human breast cancer cells in vivo but not in vitro.
    Kurebayashi J; Otsuki T; Yamamoto S; Kurosumi M; Nakata T; Akinaga S; Sonoo H
    Oncology; 1998 Dec; 55 Suppl 1():23-34. PubMed ID: 9852399
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.